Skip to content
Oncology Research Hub

Ohio

Cancer clinical trials in Ohio

542 cancer studies are recruiting participants at sites in 70 cities across Ohio as of November 16, 2026, according to ClinicalTrials.gov.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Browse Ohio by city

Cities with the most studies recruiting right now.

Every Ohio city with a recruiting study

By research area: Lung Cancer (156), Lymphoma (137), Breast Cancer (115), Prostate Cancer (62), Pancreatic Cancer (40), Melanoma (32).

Columbus (269), Cleveland (205), Cincinnati (154), Canton (68), Dayton (47), Centerville (32), Toledo (31), Franklin (29), Greenville (28), Akron (27), Troy (26), Maumee (22), Sylvania (20), West Chester (20), Mayfield Heights (19), Kettering (18), Delaware (16), Mansfield (16), Westerville (16), Avon (15), Marion (15), Zanesville (15), Dublin (14), Newark (14), Beachwood (13), Belpre (13), Chillicothe (12), Mentor (12), Perrysburg (12), Springfield (12), Marysville (11), Grove City (10), Mount Vernon (10), Portsmouth (10), Beavercreek (9), Findlay (9), Sandusky (9), Lancaster (8), Marietta (8), Pickerington (8), Youngstown (8), Athens (7), Boardman (7), Gahanna (7), Warren (7), Wooster (7), Barberton (6), Medina (6), Warrensville Heights (6), Fairfield (5), Independence (5), Lima (5), New Albany (5), Strongsville (5), Alliance (4), Massillon (4), Orange (4), Westlake (4), Chardon (3), Middleburg Heights (3), Parma (3), Ravenna (3), Steubenville (3), Wadsworth (2), Wilmington (2), Colombus (1), Fairborn (1), North Canton (1), Ohio City (1), Orrville (1).

The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.

Breast cancer: recently updated in Ohio

Basic details from each study's public record (the 12 most recently updated of 542). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    LeonaBio
    Recruiting in
    Cleveland · Columbus
    Registry record
    NCT05696626 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Ohio on ClinicalTrials.gov.

Lung cancer: recently updated in Ohio

  1. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Recruiting in
    Cincinnati · Cleveland · Columbus · and 1 more U.S. location
    Registry record
    NCT06287775 · updated
  2. A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

    • Phase 3
    • Ages 18 to 100
    • All sexes
    Sponsor
    Amgen
    Recruiting in
    Dayton
    Registry record
    NCT05920356 · updated
  3. A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Novelty Nobility, Inc.
    Recruiting in
    Cleveland
    Registry record
    NCT06805825 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Ohio on ClinicalTrials.gov.

Prostate cancer: recently updated in Ohio

  1. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Recruiting in
    Cincinnati · Columbus
    Registry record
    NCT04423211 · updated
  2. Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Cleveland
    Registry record
    NCT06136624 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Ohio on ClinicalTrials.gov.

Melanoma: recently updated in Ohio

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Recruiting in
    Avon · Beachwood · Cincinnati · and 2 more U.S. locations
    Registry record
    NCT07068074 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Ohio on ClinicalTrials.gov.

Lymphoma: recently updated in Ohio

  1. Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    John Reneau
    Recruiting in
    Columbus
    Registry record
    NCT04848064 · updated
  2. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Recruiting in
    Athens · Columbus · Delaware · and 5 more U.S. locations
    Registry record
    NCT06724237 · updated
  3. A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Nurix Therapeutics, Inc.
    Recruiting in
    Cincinnati · Cleveland · Columbus · and 1 more U.S. location
    Registry record
    NCT07221500 · updated
  4. A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

    • Phase 1
    • Ages 0 to 18
    • All sexes
    Sponsor
    Autolus Limited
    Recruiting in
    Cincinnati
    Registry record
    NCT06173518 · updated
  5. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Recruiting in
    Cincinnati
    Registry record
    NCT06717347 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Ohio on ClinicalTrials.gov.

Ask about studies in Ohio

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call